skip to main content

Amelanotic Melanoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinAmelanotic MelanomaSCE Medical Oncology

A 14-year-old has a completely resected stage IIC cutaneous melanoma, no evidence of disease on staging and no contraindication to PD-1 blockade. Which adjuvant systemic option is specifically recommended by NICE TA837?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Adjuvant pembrolizumab for the appraised treatment course

Option B is correct: TA837 recommends adjuvant pembrolizumab after complete resection of stage IIB or IIC melanoma from age 12. Option E omits an approved risk-reducing treatment. Option D is not the TA837 stage-II regimen. Option A is not the appraised adjuvant combination, and option C is not the current recommended systemic option.

Reference: NICE TA837: adjuvant pembrolizumab in stage IIB or IIC melanoma. https://www.nice.org.uk/guidance/ta837/chapter/1-Recommendations